Antibiotic susceptibilities(SUS) of group B streptococcus (GBS) and gram negative bacilli (GNB) isolated from infants(INF) born at Parkland Memorial hospital (PMH) 1987-97

J. D. Siegel, N. B. Cushion

Research output: Contribution to journalArticle

Abstract

On 1/3/95, we implemented a protocol at PMH for the prophylaxis (PRLX) of early onset GBS disease that combines the administration (ADM) of intrapartum (IP) ampicillin (AMP) to women with obstetrical risk factors and ADM of single dose penicillin (PEN) within 1 hour of delivery to all INF. We reviewed the SUS of INF isolates for GBS from 1/1/94 to 5/1/97 and for GNB 1/1/87 to 5/1/97. All SUS testing was performed by the MicroScan® system. GBS SUS were as follows: AMP (MIC ≤ 0.12), 78/78 (100%); clindamycin (MIC ≤ 0.25), 71/74 (96%); erythromycin (MIC ≤ 4), 70/73 (96%). SUS of 102 strains of E. coli, Enterobacter, Klebsiella, and Serratia sp. for AMP, cefotaxime (CTX), gentamicin (GEN), tobramycin (TOB) were compared for 1987-94 (no GBS IP AMP/PEN) vs.1995-97 (GBS IP AMP/PEN). There were no significant increases in resistance (RES) over time. AMP RES (MIC > 8) for E. coli was not significantly different between the 2 time periods: (22/46,48%) vs. (10/18,56%), p = 0.78. 6% of E. coli were resistant to GEN and TOB. All strains of Klebsiella and Serratia sp. and 79% (11/14) Enterobacter sp. from 1987-97 were resistant to AMP. The only CTX resistant strains were Enterobacter sp. (2/12,17%) and Serratia sp. (1/4,25%). We conclude that in our medical center 1) clindamycin and erythromycin will provide adequate protection against early onset GBS in INF of PEN allergic women and 2) the combined use of AMP for IP PRLX and single dose PEN at birth is not associated with increased RES of GNB causing INF sepsis.

Original languageEnglish (US)
Pages (from-to)424
Number of pages1
JournalClinical Infectious Diseases
Volume25
Issue number2
StatePublished - 1997

Fingerprint

Streptococcus agalactiae
Ampicillin
Bacillus
Anti-Bacterial Agents
Penicillins
Serratia
Enterobacter
Tobramycin
Klebsiella
Cefotaxime
Clindamycin
Erythromycin
Escherichia coli
Gentamicins
Ampicillin Resistance
Sepsis
Parturition

ASJC Scopus subject areas

  • Immunology

Cite this

@article{7fc440a48450490eb8194120dd0b9ef5,
title = "Antibiotic susceptibilities(SUS) of group B streptococcus (GBS) and gram negative bacilli (GNB) isolated from infants(INF) born at Parkland Memorial hospital (PMH) 1987-97",
abstract = "On 1/3/95, we implemented a protocol at PMH for the prophylaxis (PRLX) of early onset GBS disease that combines the administration (ADM) of intrapartum (IP) ampicillin (AMP) to women with obstetrical risk factors and ADM of single dose penicillin (PEN) within 1 hour of delivery to all INF. We reviewed the SUS of INF isolates for GBS from 1/1/94 to 5/1/97 and for GNB 1/1/87 to 5/1/97. All SUS testing was performed by the MicroScan{\circledR} system. GBS SUS were as follows: AMP (MIC ≤ 0.12), 78/78 (100{\%}); clindamycin (MIC ≤ 0.25), 71/74 (96{\%}); erythromycin (MIC ≤ 4), 70/73 (96{\%}). SUS of 102 strains of E. coli, Enterobacter, Klebsiella, and Serratia sp. for AMP, cefotaxime (CTX), gentamicin (GEN), tobramycin (TOB) were compared for 1987-94 (no GBS IP AMP/PEN) vs.1995-97 (GBS IP AMP/PEN). There were no significant increases in resistance (RES) over time. AMP RES (MIC > 8) for E. coli was not significantly different between the 2 time periods: (22/46,48{\%}) vs. (10/18,56{\%}), p = 0.78. 6{\%} of E. coli were resistant to GEN and TOB. All strains of Klebsiella and Serratia sp. and 79{\%} (11/14) Enterobacter sp. from 1987-97 were resistant to AMP. The only CTX resistant strains were Enterobacter sp. (2/12,17{\%}) and Serratia sp. (1/4,25{\%}). We conclude that in our medical center 1) clindamycin and erythromycin will provide adequate protection against early onset GBS in INF of PEN allergic women and 2) the combined use of AMP for IP PRLX and single dose PEN at birth is not associated with increased RES of GNB causing INF sepsis.",
author = "Siegel, {J. D.} and Cushion, {N. B.}",
year = "1997",
language = "English (US)",
volume = "25",
pages = "424",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Antibiotic susceptibilities(SUS) of group B streptococcus (GBS) and gram negative bacilli (GNB) isolated from infants(INF) born at Parkland Memorial hospital (PMH) 1987-97

AU - Siegel, J. D.

AU - Cushion, N. B.

PY - 1997

Y1 - 1997

N2 - On 1/3/95, we implemented a protocol at PMH for the prophylaxis (PRLX) of early onset GBS disease that combines the administration (ADM) of intrapartum (IP) ampicillin (AMP) to women with obstetrical risk factors and ADM of single dose penicillin (PEN) within 1 hour of delivery to all INF. We reviewed the SUS of INF isolates for GBS from 1/1/94 to 5/1/97 and for GNB 1/1/87 to 5/1/97. All SUS testing was performed by the MicroScan® system. GBS SUS were as follows: AMP (MIC ≤ 0.12), 78/78 (100%); clindamycin (MIC ≤ 0.25), 71/74 (96%); erythromycin (MIC ≤ 4), 70/73 (96%). SUS of 102 strains of E. coli, Enterobacter, Klebsiella, and Serratia sp. for AMP, cefotaxime (CTX), gentamicin (GEN), tobramycin (TOB) were compared for 1987-94 (no GBS IP AMP/PEN) vs.1995-97 (GBS IP AMP/PEN). There were no significant increases in resistance (RES) over time. AMP RES (MIC > 8) for E. coli was not significantly different between the 2 time periods: (22/46,48%) vs. (10/18,56%), p = 0.78. 6% of E. coli were resistant to GEN and TOB. All strains of Klebsiella and Serratia sp. and 79% (11/14) Enterobacter sp. from 1987-97 were resistant to AMP. The only CTX resistant strains were Enterobacter sp. (2/12,17%) and Serratia sp. (1/4,25%). We conclude that in our medical center 1) clindamycin and erythromycin will provide adequate protection against early onset GBS in INF of PEN allergic women and 2) the combined use of AMP for IP PRLX and single dose PEN at birth is not associated with increased RES of GNB causing INF sepsis.

AB - On 1/3/95, we implemented a protocol at PMH for the prophylaxis (PRLX) of early onset GBS disease that combines the administration (ADM) of intrapartum (IP) ampicillin (AMP) to women with obstetrical risk factors and ADM of single dose penicillin (PEN) within 1 hour of delivery to all INF. We reviewed the SUS of INF isolates for GBS from 1/1/94 to 5/1/97 and for GNB 1/1/87 to 5/1/97. All SUS testing was performed by the MicroScan® system. GBS SUS were as follows: AMP (MIC ≤ 0.12), 78/78 (100%); clindamycin (MIC ≤ 0.25), 71/74 (96%); erythromycin (MIC ≤ 4), 70/73 (96%). SUS of 102 strains of E. coli, Enterobacter, Klebsiella, and Serratia sp. for AMP, cefotaxime (CTX), gentamicin (GEN), tobramycin (TOB) were compared for 1987-94 (no GBS IP AMP/PEN) vs.1995-97 (GBS IP AMP/PEN). There were no significant increases in resistance (RES) over time. AMP RES (MIC > 8) for E. coli was not significantly different between the 2 time periods: (22/46,48%) vs. (10/18,56%), p = 0.78. 6% of E. coli were resistant to GEN and TOB. All strains of Klebsiella and Serratia sp. and 79% (11/14) Enterobacter sp. from 1987-97 were resistant to AMP. The only CTX resistant strains were Enterobacter sp. (2/12,17%) and Serratia sp. (1/4,25%). We conclude that in our medical center 1) clindamycin and erythromycin will provide adequate protection against early onset GBS in INF of PEN allergic women and 2) the combined use of AMP for IP PRLX and single dose PEN at birth is not associated with increased RES of GNB causing INF sepsis.

UR - http://www.scopus.com/inward/record.url?scp=33748174570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748174570&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748174570

VL - 25

SP - 424

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -